Percheron Therapeutics Limited Share Price OTC Markets
Equities
ATHJF
AU0000317281
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.012 USD | -84.00% | -52.00% | +20.00% |
01:44am | Percheron Therapeutics Names Chief Medical Advisor | MT |
05-29 | Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3% | MT |
Sales 2024 * | 3.6M 2.4M 188M | Sales 2025 * | 5.3M 3.54M 277M | Capitalization | 80.24M 53.56M 4.19B |
---|---|---|---|---|---|
Net income 2024 * | -17M -11.35M -888M | Net income 2025 * | -31M -20.69M -1.62B | EV / Sales 2024 * | 19.8 x |
Net cash position 2024 * | 8.92M 5.95M 466M | Net cash position 2025 * | 17.43M 11.63M 910M | EV / Sales 2025 * | 11.9 x |
P/E ratio 2024 * |
-5.68
x | P/E ratio 2025 * |
-2.26
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.66% |
1 day | -84.00% | ||
1 week | -52.00% | ||
1 month | +20.00% | ||
3 months | +20.00% | ||
6 months | -76.00% | ||
Current year | +20.00% |
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 07/05/23 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 08/11/06 |
Anthony Filippis
COO | Chief Operating Officer | - | 31/10/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 08/11/06 |
Ben Price
BRD | Director/Board Member | 68 | 03/10/21 |
James Garner
CEO | Chief Executive Officer | - | 07/05/23 |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 0.012 | -84.00% | 10,000 |
Delayed Quote OTC Markets, May 31, 2024 at 04:09 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.72% | 118B | |
+13.01% | 106B | |
-3.22% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-17.43% | 15.56B | |
+4.54% | 13.63B | |
+28.41% | 12.27B |
- Stock Market
- Equities
- PER Stock
- ATHJF Stock